Menu
A

Albert Schweitzer Ziekenhuis | Dordwijk - Cardiology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Guselkumab
Daratumumab
Carboplatin
Dexamethasone
Apixaban
Cyclophosphamide
Docetaxel
Nivolumab
Ciprofloxacin
Olezarsen

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and...

Active, not recruiting
Polycythemia Vera
Drug: Placebo
Drug: Rusfertide

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with o...

Enrolling
Type 1 Diabetes Mellitus
Biological: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
Biological: Placebo

This study will test the hypothesis that implantation of a subcutaneous implantable cardioverter defibrillator (S-ICD) without performing a defibrill...

Active, not recruiting
Ventricular Arrythmia
Procedure: ommitence of defibrillation testing

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting
Crohn's Disease
Biological: JNJ-78934804
Biological: Golimumab

The purpose of this study is to evaluate the efficacy and safety of JNJ-78934804 as compared to guselkumab and golimumab in participants with moderat...

Active, not recruiting
Colitis, Ulcerative
Biological: JNJ-78934804
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Olezarsen
Drug: Placebo

The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from ba...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen

The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free sur...

Active, not recruiting
Smoldering Multiple Myeloma
Drug: Daratumumab SC: daratumumab + rHuPH20

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Cyclophosphamide

The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel mon...

Enrolling
ST Elevated Myocardial Infarction
Dual Antiplatelet Therapy
Drug: Prasugrel based standard DAPT
Drug: Prasugrel based short DAPT

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Abemaciclib

The study aims to evaluate a modified antiplatelet therapy associated with Firehawk low-dose rapamycin DES in acute myocardial infarction patients tr...

Active, not recruiting
Coronary Artery Disease
Myocardial Infarction, Acute
Drug: Standard DAPT
Drug: Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin)

Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Active, not recruiting
Multiple Myeloma
Drug: Iberdomide plus low-dose cyclophosphamide and dexamethasone

The aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-durat...

Active, not recruiting
Chronic Lymphoid Leukemia
Biological: Obinutuzumab
Biological: Venetoclax

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination wi...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanc...

Active, not recruiting
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Drug: Sitravatinib
Drug: Docetaxel

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclis...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Teclistamab
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trial sponsors

Erasmus University logo
Janssen (J&J Innovative Medicine) logo
Netherlands Cancer Institute (NKI) logo
A
AbbVie logo
Abbott logo
Celgene logo
Genmab logo
Takeda logo
C